The expression of miR-21 before and after therapy was correlated with OS, regardless of the type of anti-HER2 treatment, and higher circulating miR-373 expression was observed in advanced stage BC, highlighting the potential role of those microRNAs in prognosis assessment. This evidence concerns the gene ERBB2 and breast cancer.